Favorable Media Coverage Somewhat Unlikely to Affect Moleculin Biotech (MBRX) Share Price
News headlines about Moleculin Biotech (NASDAQ:MBRX) have trended positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Moleculin Biotech earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2233570385268 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Corporate News Blog – Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin (finance.yahoo.com)
- Moleculin Signs Agreement with First Hospital for Annamycin Trials (finance.yahoo.com)
- Moleculin Announces FDA Approval of Annamycin IND (finance.yahoo.com)
- Today’s Research Reports on Stocks to Watch: Axovant and Moleculin (finance.yahoo.com)
- Corporate News Blog – FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AML (finance.yahoo.com)
Shares of Moleculin Biotech (NASDAQ MBRX) traded down 0.40% during mid-day trading on Friday, hitting $2.46. The stock had a trading volume of 259,565 shares. Moleculin Biotech has a 52-week low of $0.71 and a 52-week high of $6.21. The firm has a 50 day moving average price of $2.52 and a 200 day moving average price of $1.45. The firm’s market cap is $49.84 million.
Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. Equities analysts predict that Moleculin Biotech will post ($0.34) EPS for the current year.
Separately, ValuEngine upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
In related news, major shareholder Waldemar Priebe sold 100,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.70, for a total value of $170,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 20.80% of the company’s stock.
About Moleculin Biotech
Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.